Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
Rodrigues G, Oberije C, Senan S, Tsujino K, Wiersma T, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, DeRuyck K, De Dios NR, Warner A, Bradley JD, Palma DA.
Rodrigues G, et al. Among authors: senan s.
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):133-9. doi: 10.1016/j.ijrobp.2014.09.033.
Int J Radiat Oncol Biol Phys. 2015.
PMID: 25835622
Clinical Trial.